Watching brain metastases closely instead of treating them right away during drug therapy
Studies safety of close monitoring for brain metastases in people on brain-reaching drug treatment.
Key facts
- Who runs it
- University of California, Irvine
- Where
- Orange, United StatesSee the site
- Trial code
- Registry title
- PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe
- Status
- Recruiting
- People taking part
- 12 people, planned
- Started
- 4 Aug 2026
- Expected to end
- Aug 2028
- Type of study
- Observational
- Record updated
- 18 September 2026
Who can take part
The trial is looking for adults with cancer that has spread to the brain, without symptoms from it. They must be about to start a new drug treatment that may work in the brain. Radiation or surgery to the brain is held back while doctors watch closely.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Metastatic cancer that is not a blood cancer, confirmed by tissue or cell tests. At least one new or growing brain metastasis that has not been treated with surgery or radiation. No active brain metastasis larger than 3cm (1.2 in). Spread to the lining of the brain (leptomeningeal disease) is allowed. KPS performance status ≥50%. Life expectancy of ≥3 months.
- Earlier treatment
- The brain metastasis must not have had surgery or radiation before. People must not have had the planned new drug treatment before. Other drugs of a similar class may be allowed if the treating team agrees.
- Main reasons for not taking part
- Only growth of brain lesions that were already treated with surgery or radiation
- Symptoms from active brain metastases
- Needing steroids, seizure drugs or other comfort medicines for brain metastases
- Conditions that prevent having an MRI scan
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Patients must have histologically or cytologically confirmed metastatic non-hematologic malignancy
- Patients must have at least one new or progressive brain metastasis that has not received prior local therapy (surgery or radiation therapy)
- Patients must have no active brain metastasis >3cm in size
- Leptomeningeal disease is permitted
- Patients with only non-measurable disease as defined by the RANO-BM criteria are permitted so long as the clinical determination of new or progressive disease has been made by the treating team
- Patients must have no symptoms attributable to active brain metastases
- At the time of enrollment, patients must be eligible for AND planning to begin a new line of systemic therapy with potential for CNS-efficacy. Determination of potential for CNS-efficacy will be determined based on the clinical judgement of the treating physicians. Patients must have had no prior exposure to the specific systemic therapy in question at the time of enrollment, though exposure to other medications from a similar class are acceptable at the discretion of the treating team
- Patient must be planning to defer radiation therapy to trial medical therapy regardless of enrollment on trial
- Must be age ≥ 18 years
- Patients must be willing to complete MoCA and FACT-BR assessments (refer to section 4.4.1)
- Performance status: KPS performance status ≥50%
- Life expectancy of ≥3 months
- Ability to understand and willingness to sign a written informed consent document
Who cannot take part
- Patients who have only progressive growth of brain lesions that have previously been treated with surgery or radiation therapy
- Patients requiring corticosteroids, anticonvulsants, or other palliative medications related to brain metastases
- Patients with conditions that exclude them from undergoing magnetic resonance imaging
- Patients with active symptomatic brain metastases
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Brain cancer or nervous system cancer or CNS cancer
This trial is currently available in United States.
- Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, United StatesContact: Aaron Simon, MDTaking people
About the trial
What the trial wants to find out
This is a Pilot clinical trial determining the safety of an active surveillance approach to local therapy in subjects with brain metastases. These are subjects who are undergoing CNS-penetrating systemic therapy.
The group in the trial
- SingleArm
CNS-Penetrating Systemic Therapy
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study Assessing the Safety of an Active Surveillance Approach to Local Therapy in Patients With Brain Metastases Undergoing CNS-Penetrating Systemic Therapy
- Plain-language title
- Watching brain metastases closely instead of treating them right away during drug therapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07827001, who can take part
- Record updated
- 18 September 2026